VSIR and hepatocellular carcinoma: This study investigated the expression of VISTA in HCC tumors and analyzed its association with clinicopathological features, TILs in the tumor microenvironment, and clinical outcomes, which provide the basis for further VISTA blockade immunotherapies in patients with HCC.